CHDI
Listed here are over 1000 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Arbez N, Ratovitski T, Roby E, Chighladze E, Stewart JC, Ren M, Wang X, Lavery DJ, Ross CA|
Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity
Friedman A, Homma D, Bloem B, Gibb LG, Amemori KI, Hu D, Delcasso S, Truong TF, Yang J, Hood AS, Mikofalvy KA, Beck DW, Nguyen N, Nelson ED, Toro Arana SE, Vorder Bruegge RH, Goosens KA, Graybiel AM
Chronic stress alters striosome-circuit dynamics, leading to aberrant decision-making
Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ, Track-HD and Track-On Investigators
Survival end points for Huntington disease trials prior to a motor diagnosis
Chao MJ, Gillis T, Atwal RS, Mysore JS, Arjomand J, Harold D, Holmans P, Jones L, Orth M, Myers RH, Kwak S, Wheeler VC, MacDonald ME, Gusella JF, Lee JM
Haplotype-based stratification of Huntington's disease
Brown KE, Lohse KR, Mayer IMS, Strigaro G, Desikan M, Casula EP, Meunier S, Popa T, Lamy JC, Odish O, Leavitt BR, Durr A, Roos RAC, Tabrizi SJ, Rothwell JC, Boyd LA, Orth M
The reliability of commonly used electrophysiology measures
Arnerić SP, Cedarbaum JM, Khozin S, Papapetropoulos S, Hill DL, Ropacki M, Rhodes J, Dacks PA, Hudson LD, Gordon MF, Kern VD, Romero K, Vradenburg G, Au R, Karlin DR, Facheris MF, Fitzer-Attas CJ, Vitolo OV, Wang J, Miller BM, Kaye JA
Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
Wild EJ, Tabrizi SJ
Therapies targeting DNA and RNA in Huntington's disease
Wu D, Faria AV, Younes L, Mori S, Brown T, Johnson H, Paulsen JS, Ross CA, Miller MI, PREDICT-HD InvestigatorsCoordinators of the Huntington Study Group
Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease
Whittaker DS, Wang HB, Loh DH, Cachope R, Colwell CS
Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease
Pharmacol Res Perspect
October 30, 2017
5 (5) :e00344
5 (5) :e00344
PMID: 28971617
PMCID: PMC5625154
DOI: 10.1002/prp2.344
Bondulich MK, Jolinon N, Osborne GF, Smith EJ, Rattray I, Neueder A, Sathasivam K, Ahmed M, Ali N, Benjamin AC, Chang X, Dick JRT, Ellis M, Franklin SA, Goodwin D, Inuabasi L, Lazell H, Lehar A, Richard-Londt A, Rosinski J, Smith DL, Wood T, Tabrizi SJ, Brandner S, Greensmith L, Howland D, Munoz-Sanjuan I, Lee SJ, Bates GP
Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice
Warner JB 4th, Ruff KM, Tan PS, Lemke EA, Pappu RV, Lashuel HA
Monomeric Huntingtin Exon 1 has similar overall structural features for wild-type and pathological polyglutamine lengths
Schuldenzucker V, Schubert R, Muratori LM, Freisfeld F, Rieke L, Matheis T, Schramke S, Motlik J, Kemper N, Radespiel U, Reilmann R
Behavioral testing of minipigs transgenic for the Huntington gene - A three-year observational study
Ghosh R, Tabrizi SJ
Gene suppression approaches to neurodegeneration
Lee JM, Chao MJ, Harold D, Abu Elneel K, Gillis T, Holmans P, Jones L, Orth M, Myers RH, Kwak S, Wheeler VC, MacDonald ME, Gusella JF
A modifier of Huntington's disease onset at the MLH1 locus
Bresciani A, Missineo A, Gallo M, Cerretani M, Fezzardi P, Tomei L, Cicero DO, Altamura S, Santoprete A, Ingenito R, Bianchi E, Pacifici R, Dominguez C, Munoz-Sanjuan I, Harper S, Toledo-Sherman L, Park LC
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)
Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C, TRACK-HD Investigators
Design optimization for clinical trials in early-stage manifest Huntington's disease
Niccolini F, Pagano G, Fusar-Poli P, Wood A, Mrzljak L, Sampaio C, Politis M
Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies
Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S, TRACK-HD investigators, REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
Brady ST, Morfini GA
Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases
Westervelt HJ, Bernier RA, Faust M, Gover M, Bockholt HJ, Zschiegner R, Long JD, Paulsen JS, PREDICT-HD Investigators, Coordinators of the Huntington Study Group
Data quality assurance and control in cognitive research: Lessons learned from the PREDICT-HD study
Schain M, Fazio P, Mrzljak L, Amini N, Al-Tawil N, Fitzer-Attas C, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A
Revisiting the Logan plot to account for non-negligible blood volume in brain tissue
Ratovitski T, O’Meally RN, Jiang M, Chaerkady R, Chighladze E, Stewart JC, Wang X, Arbez N, Roby E, Alexandris A, Duan W, Vijayvargia R, Seong IS, Lavery DJ, Cole RN, Ross CA
Post-Translational Modifications (PTMs), identified on endogenous Huntingtin, cluster within proteolytic domains between HEAT repeats
Zheng P, Kozloski J
Striatal network models of Huntington's disease dysfunction phenotypes
Ghosh S, Sun Z, Li Y, Cheng Y, Mohan A, Sampaio C, Hu J
An exploration of latent structure in observational Huntington's disease studies
Dietrich P, Johnson IM, Alli S, Dragatsis I
Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis
Kalathur RKR, Pedro Pinto J, Sahoo B, Chaurasia G, Futschik ME
HDNetDB: A molecular interaction database for network-oriented investigations into Huntington's disease
Daldin M, Fodale V, Cariulo C, Azzollini L, Verani M, Martufi P, Spiezia MC, Deguire SM, Cherubini M, Macdonald D, Weiss A, Bresciani A, Vonsattel JG, Petricca L, Marsh JL, Gines S, Santimone I, Marano M, Lashuel HA. Squitieri F, Caricasole A
Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models
Kang H, Vázquez FX, Zhang L, Das P, Toledo-Sherman L, Luan B, Levitt M, Zhou R
Emerging β-sheet rich conformations in supercompact Huntingtin Exon-1 mutant structures
Khakh BS, Beaumont V, Cachope R, Munoz-Sanjuan I, Goldman SA, Grantyn R
Unravelling and exploiting astrocyte dysfunction in Huntington's disease
Dominguez D JF, Poudel G, Stout JC, Gray M, Chua P, Borowsky B, Egan GF, Georgiou-Karistianis N
Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington's disease : 30 months IMAGE-HD data
Nikan M, Osborn MF, Coles AH, Biscans A, Godinho BMDC, Haraszti RA, Sapp E, Echeverria D, DiFiglia M, Aronin N, Khvorova A
Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA conjugate in mouse brain
Teka WW, Hamade KC, Barnett WH, Kim T, Markin SN, Rybak IA, Molkov YI
From the motor cortex to the movement and back again
Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ
Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
Lancet Neurol
June 7, 2017
17 (30124-2) :S1474-4422
17 (30124-2) :S1474-4422
PMID: 28601473
Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG
KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients
Proc Natl Acad Sci USA
June 6, 2017
114 (23) :E4676-E4685
114 (23) :E4676-E4685
PMID: 28533375
Park KHJ, Franciosi S, Parrant K, Lu G, Leavitt BR
p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease
Farina F, Lambert E, Commeau L, Lejeune FX, Roudier N, Fonte C, Parker JA, Boddaert J, Verny M, Baulieu EE, Neri C
The stress response factor daf-16 FOXO is required for multiple compound families to prolong the function of neurons with Huntington's disease
Cleary JD, Ranum LP
New developments in RAN translation: insights from multiple diseases
McColgan P, Razi A, Gregory S, Seunarine KK, Durr A, Roos ACR, Leavitt BR, Scahill RI, Clark CA, Langbehn DR, Rees G, Tabrizi SJ, Track On-HD Investigators
Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease
Hum Brain Mapp
June 1, 2017
38 (6) :2819-2829
38 (6) :2819-2829
PMID: 28294457
PMCID: PMC5434856
DOI: 10.1002/hbm.23527
Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, Fitzer-Attas CJ, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A
Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D(2/3) receptors and sub-cortical volumes in the human basal ganglia: A PET study with (18)F-MNI-659 and (11)C-raclopride with correction for partial volume effect
Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, Tabrizi SJ, Bates GP
The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients